CTXR

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a specialty pharmaceutical company founded in 2007 and headquartered in Cranford, New Jersey. The company went public in October 2014 and focuses on developing critical care products, particularly anti-infective treatments for cancer care, prescription therapeutics, and advanced stem cell therapies. As a clinical-stage biotechnology company, Citius has built a pipeline of five proprietary products targeting various medical conditions, from catheter-related infections to cancer treatments, though it has yet to generate substantial commercial revenues from these developments.